Related Experiment Video
Updated: Feb 2, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Genomic classification and risk stratification of bladder cancer
Damiano Fantini1,2,3, Joshua J Meeks4,5,6,7
1Department of Urology, Feinberg School of Medicine, Chicago, IL, USA.
Abstract:
Bladder cancer is the fourth most common cancer in men and fifth most common overall. The use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the molecular defects of tumors, and this information could be combined with other clinical data, such as tumor histology and TNM staging, with the goal of precise tumor classification. In many settings, targeted NGS is evaluated in patients with first- and second-line metastatic cancer. Yet, in the decade to come we anticipate increased application of precision oncology at all stages of bladder cancer with the aim of customizing cancer treatment. Here, we review the genomic and transcriptomic features associated with risk stratification in bladder cancer and summarize the current efforts for precision oncology in localized urothelial carcinomas.
Insights
Next-generation sequencing (NGS) precisely characterizes bladder cancer molecular defects for improved classification. Precision oncology will increasingly customize bladder cancer treatment across all stages, integrating genomic data with clinical information.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Bladder cancer is a significant health concern, ranking as the fourth most common cancer in men and fifth overall.
- Accurate molecular characterization of tumors is essential for precise classification and treatment.
- Current applications of targeted next-generation sequencing (NGS) are primarily in metastatic bladder cancer settings.
Purpose of the Study:
- To review genomic and transcriptomic features for bladder cancer risk stratification.
- To summarize current precision oncology efforts in localized urothelial carcinomas.
- To highlight the anticipated expansion of precision oncology in bladder cancer treatment.
Main Methods:
- Review of genomic and transcriptomic data in bladder cancer.
- Analysis of molecular defects using next-generation sequencing (NGS).
- Integration of molecular data with clinical information like histology and TNM staging.
Main Results:
- NGS enables precise characterization of tumor molecular defects.
- Genomic and transcriptomic features are key for risk stratification.
- Precision oncology approaches are evolving for bladder cancer.
Conclusions:
- Precision oncology holds significant promise for customizing bladder cancer treatment.
- The application of precision oncology is expected to increase across all stages of bladder cancer.
- Further integration of molecular and clinical data will enhance bladder cancer management.
Related Concept Videos
Genomics
Relative Risk
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Force Classification
Contact and non-contact forces are two of the most widely used categories of forces. As the name suggests, contact forces require physical contact between two objects to act upon each other. Examples of contact forces include frictional,...
Classification of Neurotransmitters

